• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Drug-Eluting Balloons

Ex-Lutonix R&D veep Barry pleads guilty to trade secret theft

May 10, 2017 By Brad Perriello

The former vice president of R&D for drug-coated balloon maker Lutonix, Christopher Barry, yesterday pleaded guilty to a single count of trade secret theft in federal court in Minneapolis. Barry, who left Lutonix in 2015 to become CEO of Urotronic, admitted to downloading 6 files in April 2015 containing trade secrets about the development of […]

Filed Under: Drug-Device Combinations, Legal News Tagged With: C.R. Bard, Drug-Eluting Balloons, Lutonix Inc., urotronic

How Boston Sci is getting drug-eluting stents and balloons into legs

April 13, 2017 By Chris Newmarker

Boston Scientific officials think they have a leg up when it comes to bringing drug-eluting technology to bear on peripheral artery disease. That’s because the medical device giant has decades of experience with balloons and drug-eluting stents used around the heart. When it comes to treating the narrowing arteries in the legs and thighs, Boston […]

Filed Under: Business/Financial News, Cardiovascular, Catheters, Contract Manufacturing, Drug-Device Combinations, Drug-Eluting Stents, News Well, Stents Tagged With: Boston Scientific, Drug-Eluting Balloons, drug-eluting stents

Spectranetics wins CE Mark for smaller Stellarex DCB

November 22, 2016 By Brad Perriello

Spectranetics (NSDQ:SPNC) said yesterday that it won CE Mark approval in the European Union for a smaller size of its Stellarex drug-coated balloon. The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease and challenging critical limb ischemia. The larger, 0.035” device won CE Mark approval in December 2014, just before Spectranetics paid Covidien $30 million deal […]

Filed Under: Regulatory/Compliance, Vascular Tagged With: Drug-Eluting Balloons, Peripheral, Spectranetics Corp.

TCT 2016: Structural heart, drug-coated balloons take their turn on Day 3

November 2, 2016 By Brad Perriello

The annual Transcatheter Cardiovascular Therapeutics conference is under way in Washington, D.C., with late-breaking study results beginning Oct. 29. We’ll update this post throughout the day as new results come in, so be sure to check back for the latest news out of TCT 2016. After stents took center stage Day 1, with a raft of […]

Pages: Page 1 Page 2 Page 3 Page 4

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Drug-Device Combinations Tagged With: Drug-Eluting Balloons, TCT 2016, Transcatheter Cardiovascular Therapeutics symposium (TCT)

Medtronic touts In.Pact Admiral DCB data

November 2, 2015 By Brad Perriello

Medtronic (NYSE:MDT) today touted data from a pair of studies of its In.Pact Admiral drug-coated balloon, presented today at the annual Vascular Interventional Advances conference in Las Vegas. Researchers revealed the formal cost-effectiveness analysis of the U.S. cohort of Medtronic’s In.Pact SFA trial, and in-stent restenosis cohort data from its In.Pact Global study. Medtronic said the 2-year, […]

Filed Under: Clinical Trials Tagged With: Drug-Eluting Balloons, Medtronic, Peripheral, Vascular Interventional Advances (VIVA)

TCT 2015: Two-year results from Medtronic’s In.Pact SFA trial

October 14, 2015 By Brad Perriello

Two-year results from Medtronic‘s (NYSE:MDT) In.Pact SFA study showed that  the drug-eluting balloon was better than conventional balloon angioplasty, researchers said today at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco. The 331-patient study randomized subjects 2:1 to either treatment with Medtronic’s In.Pact Admiral DEB or standard angioplasty. The primary efficacy endpoint was primary patency, […]

Filed Under: Cardiovascular Tagged With: Drug-Eluting Balloons, Medtronic, TCT 2015

TCT 2015: More 2-year data on Bard’s Lutonix DEB

October 13, 2015 By Brad Perriello

C.R. Bard (NYSE:BCR) yesterday released 2-year results from a small group of patients in a real-world registry study of its Lutonix drug-eluting balloon at the annual Transcatheter Cardiovascular Therapeutics conference in San Franscisco. Bard said the Lutonix 035 device, which is designed to treat peripheral artery disease, showed a 94.3% rate of freedom from target lesion revascularization in […]

Filed Under: Cardiovascular, Clinical Trials Tagged With: C.R. Bard, Drug-Eluting Balloons, Peripheral, TCT 2015

Spectranetics to boost Stellarex spend

April 24, 2015 By Brad Perriello Leave a Comment

Spectranetics to boost Stellarex spend

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2015, Covidien, Drug-Eluting Balloons, Q1, Spectranetics Corp.

Bard shares tick up on Q1 earnings beat

April 24, 2015 By Brad Perriello Leave a Comment

Bard shares tick up on Q1 earnings beat

C.R. Bard (NYSE:BCR) shares gained today after the medical products giant reported 1st-quarter earnings that topped expectations on Wall Street, despite a poor quarterly comparison for its Lutonix drug-eluting balloon.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2015, C.R. Bard, Drug-Eluting Balloons, Q1

Spectranetics touts Stellarex drug-eluting balloon data

April 21, 2015 By Mark Hollmer Leave a Comment

Spectranetics touts Stellarex drug-eluting balloon data

Filed Under: News Well Tagged With: Clinical Trials, Covidien, Drug-Eluting Balloons, Peripheral, Spectranetics Corp.

PAD: Medtronic launches In.Pact Admiral DEB in the U.S.

February 4, 2015 By Brad Perriello Leave a Comment

PAD: Medtronic launches In.Pact Admiral DEB in the U.S.

Filed Under: News Well Tagged With: Drug-Eluting Balloons, Peripheral

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy